Septin-5 Antibody, Tissue Immunofluorescence, Spinal Fluid
Use
Septin-5 IgG is a biomarker of a rapidly progressive, but treatable, form of autoimmune cerebellar ataxia. Patients present with subacute onset of cerebellar ataxia with prominent eye movement symptoms (oscillopsia or vertigo). Improvement may occur after immunotherapy. Detecting septin-5 IgG in spinal fluid (CSF) specimens and reporting an end titer result from CSF specimens can aid in the diagnosis of autoimmune disease of the central nervous system.
Special Instructions
Only orderable as a reflex. For more information see MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.
Limitations
Negative results for septin antibodies do not exclude neurological autoimmunity or cancer. Seropositivity for septin antibodies by indirect immunofluorescence is consistent with a diagnosis of autoimmune disease of the central nervous system, but cell-binding assay testing for septin-5 IgG is required to confirm the diagnosis.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay)
Biomarkers
LOINC Codes
- 101459-6
- 101459-6
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1.5 mL
Minimum Volume
Not provided
Container
Sterile vial
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |